摘要
目的比较罗沙司他与促红素治疗血液透析患者肾性贫血的临床疗效。方法选取2022年1月-12月龙南市第一人民医院收治的78例血液透析合并肾性贫血患者临床资料,根据治疗方式不同分为对照组、观察组,每组39例。对照组给予促红素治疗,观察组给予罗沙司他治疗。比较两组铁代谢指标[铁调素(Hepc)、转铁蛋白(TRF)、转铁蛋白饱和度(TSAT)、血清铁蛋白(SF)]、贫血指标[红细胞比容(Hct)、血红蛋白(Hb)与红细胞计数(RBC)]以及不良反应(心力衰竭、头疼、恶心、腹泻)发生情况。结果观察组治疗后Hepc水平低于对照组,TRF、TSAT、SF水平均高于对照组,差异有统计学意义(P<0.05);观察组治疗后Hct、Hb、RBC水平均高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率(5.13%)低于对照组(28.21%),差异有统计学意义(P<0.05)。结论相较于促红素治疗,罗沙司他治疗血液透析患者肾性贫血的疗效更加理想,利于改善机体铁代谢与贫血状况,且用药安全性高。
Objective To compare the clinical efficacy of rosalrestat and erythropoietin in the treatment of renal anemia in hemodialysis patients.Methods The clinical data of 78 hemodialysis patients with renal anemia admitted to Longnan First People's Hospital from January to December 2022 were selected and divided into control group and observation group according to different treatment methods,with 39 patients in each group.The control group was treated with erythropoietin,and the observation group was treated with rosalrestat.The iron metabolism indexes[hepcidin(Hepc),transferrin(TRF),transferrin saturation(TSAT),serum ferritin(SF)],anemia indexes[hematocrit(Hct),hemoglobin(Hb)and red blood cell count(RBC)]and adverse reactions(heart failure,headache,nausea,diarrhea)were compared between the two groups.Results After treatment,the level of Hepc in the observation group was lower than that in the control group,and the levels of TRF,TSAT and SF were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of Hct,Hb and RBC in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group(5.13%)was lower than that in the control group(28.21%),and the difference was statistically significant(P<0.05).Conclusion Compared with erythropoietin,rosalrestat is more effective in the treatment of renal anemia in hemodialysis patients,which is beneficial to improve iron metabolism and anemia,and has high safety.
作者
叶益舟
凌铭培
余娟
李小生
YE Yi-zhou;LING Ming-pei;YU Juan;LI Xiao-sheng(Department of Nephrology,Longnan First People's Hospital,Longnan 341700,Jiangxi,China)
出处
《医学信息》
2024年第16期52-54,63,共4页
Journal of Medical Information
基金
赣州市科技计划项目(编号:GZ2023ZSF470)。
关键词
罗沙司他
促红素
血液透析
肾性贫血
铁代谢
Rosalrestat
Erythropoietin
Hemodialysis
Renalanemia
Iron metabolism
